HHS Won't Invoke IP Rights To Lessen Xtandi Prices
The U.S. Department of Health and Human Services said it's unnecessary for the government to assert patent rights to Pfizer and Astellas' blockbuster cancer drug, Xtandi, in the hopes of lowering...To view the full article, register now.
Already a subscriber? Click here to view full article